[go: up one dir, main page]

MX2012007375A - 3-ceto-n-propargil 1-aminoindano. - Google Patents

3-ceto-n-propargil 1-aminoindano.

Info

Publication number
MX2012007375A
MX2012007375A MX2012007375A MX2012007375A MX2012007375A MX 2012007375 A MX2012007375 A MX 2012007375A MX 2012007375 A MX2012007375 A MX 2012007375A MX 2012007375 A MX2012007375 A MX 2012007375A MX 2012007375 A MX2012007375 A MX 2012007375A
Authority
MX
Mexico
Prior art keywords
aminoindan
keto
propargyl
salt
proï
Prior art date
Application number
MX2012007375A
Other languages
English (en)
Inventor
Ramy Lidor Hadas
Eliezer Bahar
Anton Frenkel
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2012007375A publication Critical patent/MX2012007375A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C221/00—Preparation of compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención actual proporciona una composición farmacéutica que contiene N-propargil-1(R)-aminoindano o una sal farmacéuticamente aceptable del mismo, y un compuesto de 3-ceto-N-propargil-1-aminoi ndano o una sal del mismo.
MX2012007375A 2009-12-22 2010-12-21 3-ceto-n-propargil 1-aminoindano. MX2012007375A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28475709P 2009-12-22 2009-12-22
US39377110P 2010-10-15 2010-10-15
PCT/US2010/061565 WO2011087791A1 (en) 2009-12-22 2010-12-21 3-keto-n-propargyl-1-aminoindan

Publications (1)

Publication Number Publication Date
MX2012007375A true MX2012007375A (es) 2012-07-30

Family

ID=44151964

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007375A MX2012007375A (es) 2009-12-22 2010-12-21 3-ceto-n-propargil 1-aminoindano.

Country Status (7)

Country Link
US (2) US20110152381A1 (es)
EP (2) EP2939669A1 (es)
AU (2) AU2010341499A1 (es)
CA (1) CA2785501A1 (es)
HK (1) HK1216005A1 (es)
MX (1) MX2012007375A (es)
WO (1) WO2011087791A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
US8809310B2 (en) * 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
EP2007369A4 (en) 2006-04-03 2009-07-01 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF LEG SYNDROME WITHOUT REST
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
UA97502C2 (ru) * 2006-12-14 2012-02-27 Тева Фармасьютікл Індастріз, Лтд. Кристаллическая твердая основа разагилина
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
JP2010538067A (ja) * 2007-09-05 2010-12-09 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンを使用する緑内障の治療方法
US20090181086A1 (en) * 2008-01-11 2009-07-16 Muhammad Safadi Rasagiline formulations, their preparation and use
ES2389353T3 (es) * 2008-06-10 2012-10-25 Teva Pharmaceutical Industries Ltd. Cápsulas de gelatina blanda de rasagilina
WO2009151625A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline for parkinson's disease modification
US8334409B2 (en) * 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
CN102065853A (zh) * 2008-06-19 2011-05-18 泰华制药工业有限公司 制备和干燥固体雷沙吉兰碱的方法
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
ES2503015T3 (es) 2009-07-09 2014-10-06 Ratiopharm Gmbh Sales de rasagilina y sus preparaciones farmacéuticas
WO2012015946A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
CA2806740A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
US8901352B2 (en) 2011-01-13 2014-12-02 Nobel Ilaç Sanayii Ve Ticaret A.S. Method for the synthesis of rasagiline
MX2014004308A (es) * 2011-10-10 2014-07-24 Teva Pharma R(+)-n-formil-propargil-aminoindan.
EP2766004A4 (en) 2011-10-10 2015-04-22 Teva Pharma R (+) - N-methyl-propargyl-aminoindan
EA201491734A1 (ru) * 2012-03-21 2015-01-30 Синтон Бв Стабилизированные фармацевтические композиции, содержащие соли разагилина
US9308182B2 (en) 2012-08-17 2016-04-12 Teva Pharmaceutical Industries, Ltd. Parenteral formulations of rasagiline

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
EP2526944B1 (en) * 2002-11-15 2016-06-01 Teva Pharmaceutical Industries Limited Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
JP2008507586A (ja) 2004-07-26 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド ラサグリンを含む、医薬投与剤
ZA200704917B (en) * 2004-11-24 2008-11-26 Teva Pharma Rasagiline orally disintegrating compositions
US7491847B2 (en) * 2005-11-17 2009-02-17 Teva Pharmaceutical Industries, Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
NZ577623A (en) * 2006-12-14 2011-05-27 Teva Pharma Tannate salt of rasagiline
UA97502C2 (ru) * 2006-12-14 2012-02-27 Тева Фармасьютікл Індастріз, Лтд. Кристаллическая твердая основа разагилина
US20090181086A1 (en) 2008-01-11 2009-07-16 Muhammad Safadi Rasagiline formulations, their preparation and use
WO2009141737A2 (en) * 2008-05-23 2009-11-26 Medichem, S.A. A new method for obtaining an aminoindan mesylate derivative
ES2389353T3 (es) * 2008-06-10 2012-10-25 Teva Pharmaceutical Industries Ltd. Cápsulas de gelatina blanda de rasagilina
WO2009151625A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline for parkinson's disease modification
CN102065853A (zh) 2008-06-19 2011-05-18 泰华制药工业有限公司 制备和干燥固体雷沙吉兰碱的方法
US8334409B2 (en) * 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
EP2657221A1 (en) 2008-11-20 2013-10-30 Dr. Reddy's Laboratories Ltd. Preparation of rasagiline and salts thereof
DE102008064061A1 (de) * 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
AU2010304755A1 (en) * 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
WO2012015946A1 (en) * 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
CA2806740A1 (en) * 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
BR112013010308A2 (pt) * 2010-10-26 2016-07-05 Teva Pharma rasagilina de deutério enriquecido
EP2766004A4 (en) * 2011-10-10 2015-04-22 Teva Pharma R (+) - N-methyl-propargyl-aminoindan
MX2014004308A (es) * 2011-10-10 2014-07-24 Teva Pharma R(+)-n-formil-propargil-aminoindan.
BR112014008550A2 (pt) * 2011-10-10 2017-04-18 Teva Pharma citramida rasagilina

Also Published As

Publication number Publication date
HK1216005A1 (en) 2016-10-07
US20110152381A1 (en) 2011-06-23
AU2016238863A1 (en) 2016-10-27
EP2515891A4 (en) 2013-06-05
WO2011087791A1 (en) 2011-07-21
EP2515891A1 (en) 2012-10-31
AU2010341499A1 (en) 2012-08-09
EP2939669A1 (en) 2015-11-04
US20150045445A1 (en) 2015-02-12
CA2785501A1 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
MX2011011136A (es) Eteres diarilicos.
AU2012259422A8 (en) Solid forms of a pharmaceutically active substance
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
PH12013500870A1 (en) Heterocyclic compounds and uses thereof
TW200745078A (en) Isoindole-imide compounds and compositions comprising and methods of using the same
MX2012004420A (es) Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes.
MX2012007161A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MY151986A (en) Adamantyl diamide derivatives and uses of same
PH12014500215B1 (en) Notch pathway signaling inhibitor compound
TN2012000392A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
MY145795A (en) Pyrazoline compounds
HK1200314A1 (en) R(+)-n-methyl-propargyl-aminoindan
MY160392A (en) Triptolide prodrugs
WO2013055687A3 (en) R(+)-n-formyl-propargyl-aminoindan
TN2012000105A1 (en) Spirolactam derivatives and uses of same
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
MX2014013664A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.
MX2012011382A (es) Nuevo polimero.
GB201020397D0 (en) Compounds
PH12013500210A1 (en) Highly crystalline valsartan
MY150776A (en) Combination of a bis-thiazolium salt or a precursor thereof and artemisinin or a derivative thereof for treating acute malaria
TW200638932A (en) CCI-779 polymorph and use thereof

Legal Events

Date Code Title Description
FA Abandonment or withdrawal